Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292864 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL6045193 | 0.87 | — | — | |
| Bromide SCHEMBL5490789 | 0.87 | — | — | |
| SCHEMBL22199552 | 0.81 | CA1 (0.40) | RECQLMAOAMAOB | |
| SCHEMBL22339735 | 0.81 | MEN1 (0.46) | RECQLMAOAMAOB | |
| Acetic Acid SCHEMBL10662111 | 0.80 | TERT (0.36) | MAOAMAOB | |
| Acetic Acid SCHEMBL10659181 | 0.80 | TERT (0.36) | MAOAMAOB | |
| SCHEMBL12661037 | 0.80 | KDM4E (0.40) | F2KDM4EMAPK1HIF1APAOX | |
| SCHEMBL21689227 | 0.80 | F2 (0.36) | F2KDM4EMAPK1HIF1ACRBN | |
| SCHEMBL31047740 | 0.80 | SOST (0.36) | KDM4EPAOXALDH1A1LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777876-B1 | N-ACYLDIPEPTIDE DERIVATIVES AND THEIR USES | NEOSTRATA COMPANY INC (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2020245843-A1 | CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE | Indian Institute Of Science Education And Research Bhopal (IN) | 2020-12-10 | — | — | WO | disclosed |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-3466976-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2019-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | F2 4471/4885KDM4E 4665/4885MAPK1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.